Labiana Health (XMAD:LAB) Dividend Payout Ratio : 0.00 (As of Dec. 2022)

View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Dividend Payout Ratio?

Labiana Health's dividend payout ratio for the months ended in Dec. 2022 was 0.00.

The historical rank and industry rank for Labiana Health's Dividend Payout Ratio or its related term are showing as below:

XMAD:LAB's Dividend Payout Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.335
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-05), the Dividend Yield % of Labiana Health is 0.00%.

Labiana Health's Dividends per Share for the months ended in Dec. 2022 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Labiana Health Dividend Payout Ratio Historical Data

The historical data trend for Labiana Health's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Dividend Payout Ratio Chart

Labiana Health Annual Data

Trend

Dec20

Dec21

Dec22

Dividend Payout Ratio

Labiana Health Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22
Dividend Payout Ratio	-	-	-	-

Competitive Comparison of Labiana Health's Dividend Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Labiana Health's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Labiana Health's Dividend Payout Ratio falls into.

Labiana Health Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Labiana Health's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-0.839
	=	N/A

Labiana Health's Dividend Payout Ratio for the quarter that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2022 )	/	EPS without NRI (Q: Dec. 2022 )
	=	0	/	-0.671
	=	N/A

Labiana Health (XMAD:LAB) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Labiana Health Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Labiana Health's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Labiana Health (XMAD:LAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Dividend Payout Ratio

Traded in Other Exchanges

N/A

Address

Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023

Website

https://www.labiana.com

Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.